B Braun recently announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the Introcan Safety 2 deep access intravenous (IV) catheter, the newest addition to the Introcan Safety 2 IV catheter portfolio.
The Introcan Safety 2 deep access IV catheter merges the trusted technologies of the original Introcan Safety 2 Multi-Access and Introcan Safety deep access catheters, offering clinicians an advanced solution that combines the strengths of both devices. This innovative catheter provides fully automatic passive safety needlestick protection and multi-access blood control in longer lengths and is designed to access deeper veins in patients with difficult vascular access and to achieve longer dwell times.
The Introcan Safety deep access IV catheter has been shown to increase peripheral intravenous catheter (PIVC) dwell times to approximately 5.7 days—compared to 3.8 days for standard long PIVCs—to help reduce PIVC restarts and help reduce escalation to more costly, invasive devices such as peripherally inserted central catheters (PICC). The multi-access blood control hub in the Introcan Safety 2 deep access PIVC is designed to minimise blood exposure and reduce the need for cleanup of blood throughout IV therapy, and there is no need to occlude the vessel during insertion or any time the hub is accessed.
“We are excited to broaden our Introcan Safety 2 IV catheter portfolio, allowing our customers to benefit from passive safety and blood exposure protection with deep access technology,” said Chad Laity, director of marketing, vascular access, IV systems and securement. “By offering a reliable solution for challenging cases, we aim to help improve patient outcomes and reduce the need for more complex procedures.”
